Matches in SemOpenAlex for { <https://semopenalex.org/work/W3122882509> ?p ?o ?g. }
- W3122882509 endingPage "319" @default.
- W3122882509 startingPage "319" @default.
- W3122882509 abstract "The dysregulation of epigenetic modifications has a well-established role in the development and progression of hematological malignancies and of solid tumors. In this context, EZH1/2 inhibitors have been designed to interfere with EZH1/2 enzymes involved in histone methylation (e.g., H3K27me3), leading to tumor growth arrest or the restoration of tumor suppressor gene transcription. However, these compounds also affect normal hematopoiesis, interfering with self-renewal and differentiation of CD34+-Hematopoietic Stem/Progenitor Cells (HSPC), and, in turn, could modulate the generation of potential anti-tumor effector lymphocytes. Given the important role of NK cells in the immune surveillance of tumors, it would be useful to understand whether epigenetic drugs can modulate NK cell differentiation and functional maturation. CD34+-HSPC were cultured in the absence or in the presence of the EZH1/2 inhibitor UNC1999 and EZH2 inhibitor GSK126. Our results show that UNC1999 and GSK126 increased CD56+ cell proliferation compared to the control condition. However, UNC1999 and GSK 126 favored the proliferation of no-cytotoxic CD56+ILC3, according to the early expression of the AHR and ROR-γt transcription factors. Our results describe novel epigenetic mechanisms involved in the modulation of NK cell maturation that may provide new tools for designing NK cell-based immunotherapy." @default.
- W3122882509 created "2021-02-01" @default.
- W3122882509 creator A5021080462 @default.
- W3122882509 creator A5027162539 @default.
- W3122882509 creator A5038566079 @default.
- W3122882509 creator A5039434552 @default.
- W3122882509 creator A5040001727 @default.
- W3122882509 creator A5040371922 @default.
- W3122882509 creator A5085307942 @default.
- W3122882509 date "2021-01-16" @default.
- W3122882509 modified "2023-09-30" @default.
- W3122882509 title "EZH1/2 Inhibitors Favor ILC3 Development from Human HSPC-CD34+ Cells" @default.
- W3122882509 cites W1490559159 @default.
- W3122882509 cites W1577253557 @default.
- W3122882509 cites W1601321489 @default.
- W3122882509 cites W1968720897 @default.
- W3122882509 cites W1971514891 @default.
- W3122882509 cites W1973210209 @default.
- W3122882509 cites W2008692412 @default.
- W3122882509 cites W2011363188 @default.
- W3122882509 cites W2022712483 @default.
- W3122882509 cites W2027877663 @default.
- W3122882509 cites W2035197415 @default.
- W3122882509 cites W2037100063 @default.
- W3122882509 cites W2039309887 @default.
- W3122882509 cites W2042580931 @default.
- W3122882509 cites W2064104881 @default.
- W3122882509 cites W2092705670 @default.
- W3122882509 cites W2099869529 @default.
- W3122882509 cites W2103021272 @default.
- W3122882509 cites W2104016369 @default.
- W3122882509 cites W2117247812 @default.
- W3122882509 cites W2120344463 @default.
- W3122882509 cites W2125474740 @default.
- W3122882509 cites W2153147102 @default.
- W3122882509 cites W2156106286 @default.
- W3122882509 cites W2159040226 @default.
- W3122882509 cites W2199397492 @default.
- W3122882509 cites W2202401513 @default.
- W3122882509 cites W2253596385 @default.
- W3122882509 cites W2273004055 @default.
- W3122882509 cites W2292659101 @default.
- W3122882509 cites W2294927533 @default.
- W3122882509 cites W2298618221 @default.
- W3122882509 cites W2318250120 @default.
- W3122882509 cites W2345615811 @default.
- W3122882509 cites W2352290668 @default.
- W3122882509 cites W2464909413 @default.
- W3122882509 cites W2531198037 @default.
- W3122882509 cites W2601892854 @default.
- W3122882509 cites W2605166062 @default.
- W3122882509 cites W2613020405 @default.
- W3122882509 cites W2619107737 @default.
- W3122882509 cites W2737220388 @default.
- W3122882509 cites W2768365920 @default.
- W3122882509 cites W2768384512 @default.
- W3122882509 cites W2782187941 @default.
- W3122882509 cites W2796494566 @default.
- W3122882509 cites W2797292560 @default.
- W3122882509 cites W2807710457 @default.
- W3122882509 cites W2807825632 @default.
- W3122882509 cites W2810497885 @default.
- W3122882509 cites W2888230996 @default.
- W3122882509 cites W2888376450 @default.
- W3122882509 cites W2889050120 @default.
- W3122882509 cites W2890499629 @default.
- W3122882509 cites W2891924787 @default.
- W3122882509 cites W2895148148 @default.
- W3122882509 cites W2907689723 @default.
- W3122882509 cites W2913744515 @default.
- W3122882509 cites W2946946191 @default.
- W3122882509 cites W2949577911 @default.
- W3122882509 cites W2953163885 @default.
- W3122882509 cites W2963448028 @default.
- W3122882509 cites W2970734757 @default.
- W3122882509 cites W2990668369 @default.
- W3122882509 cites W2991638976 @default.
- W3122882509 cites W2993601816 @default.
- W3122882509 cites W3000339487 @default.
- W3122882509 cites W3005525322 @default.
- W3122882509 cites W3013500379 @default.
- W3122882509 cites W3022815904 @default.
- W3122882509 cites W3037919768 @default.
- W3122882509 cites W3087177675 @default.
- W3122882509 doi "https://doi.org/10.3390/cancers13020319" @default.
- W3122882509 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7830003" @default.
- W3122882509 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33467134" @default.
- W3122882509 hasPublicationYear "2021" @default.
- W3122882509 type Work @default.
- W3122882509 sameAs 3122882509 @default.
- W3122882509 citedByCount "7" @default.
- W3122882509 countsByYear W31228825092021 @default.
- W3122882509 countsByYear W31228825092022 @default.
- W3122882509 crossrefType "journal-article" @default.
- W3122882509 hasAuthorship W3122882509A5021080462 @default.
- W3122882509 hasAuthorship W3122882509A5027162539 @default.
- W3122882509 hasAuthorship W3122882509A5038566079 @default.
- W3122882509 hasAuthorship W3122882509A5039434552 @default.